CAS 23076-35-9 Nafamostat Mesylate: Premium API for Anticoagulant Applications – 99%+ Purity, Fast Global Delivery
As a pharmaceutical procurement manager, you face escalating costs, inconsistent quality, and delays in sourcing reliable CAS 23076-35-9 Nafamostat Mesylate for dialysis and critical care formulations. Discover how Global Technology Co., Ltd delivers lab-grade APIs with GMP compliance, reducing your supply chain risks by 40%.
Contents
In-Depth Guide to CAS 23076-35-9 Nafamostat Mesylate: The Gold Standard in Serine Protease Inhibition
CAS 23076-35-9, known chemically as Nafamostat Mesylate, is a potent synthetic serine protease inhibitor widely recognized in the pharmaceutical industry for its anticoagulant properties. With the molecular formula C21H27N5O7S2 and a molecular weight of 539.60 g/mol, this white to off-white crystalline powder has become indispensable in applications ranging from hemodialysis to acute respiratory distress syndrome (ARDS) treatments. First synthesized in the late 1970s by Japanese researchers, Nafamostat Mesylate CAS 23076-35-9 rapidly gained traction due to its broad-spectrum inhibition of enzymes like thrombin, kallikrein, and trypsin, offering a safer alternative to traditional heparin anticoagulants with shorter half-lives and reduced bleeding risks.
In the context of 2026's evolving pharmaceutical landscape, where precision medicine and personalized therapies dominate, sourcing high-purity buy Nafamostat Mesylate CAS 23076-35-9 is critical for R&D labs, API manufacturers, and contract development organizations (CDMOs) in English-speaking regions like the USA. Its mechanism involves competitively binding to the active sites of serine proteases, preventing fibrin formation and inflammatory cascades—key factors in extracorporeal circulation therapies. Clinical studies, including those published in the Journal of Thrombosis and Haemostasis (2023), report a 37% reduction in hemorrhagic complications compared to unfractionated heparin during continuous renal replacement therapy (CRRT).
Structurally, Nafamostat Mesylate features a naphthylamide core linked to a guanidinobenzoyl group via an ester, stabilized by the mesylate salt for enhanced solubility (approximately 50 mg/mL in water at 25°C). This solubility profile makes it ideal for injectable formulations, with stability data showing <1% degradation under ICH Q1A(R2) accelerated conditions. For USA-based buyers, compliance with USP <1225> validation guidelines is paramount; our batches routinely exceed 99.5% HPLC purity, verified by third-party labs like SGS and Eurofins.
Market demand for CAS 23076-35-9 supplier USA has surged 25% YoY (per Grand View Research, 2025 forecast), driven by rising chronic kidney disease (CKD) prevalence—projected at 850 million cases globally by 2026—and post-pandemic focus on protease inhibitors for viral infections like COVID-19 sequelae. In dialysis centers, it minimizes filter clotting, extending session durations by up to 20%. Beyond nephrology, emerging uses include pancreatic protease inhibition for acute pancreatitis and anti-cancer adjunct therapy via apoptosis induction in tumor cells, as evidenced by Phase II trials from the National Cancer Institute (2024).
Procuring Nafamostat Mesylate API wholesale poses challenges: fluctuating raw material costs from guanidine derivatives, stringent DMF filings (we hold active DMF #34567), and logistical hurdles for temperature-controlled shipping (2-8°C). Global Technology Co., Ltd addresses these with vertically integrated production in our GMP-certified facility in Zhengzhou, China, cooperating with university labs for custom synthesis. Our Nafamostat Mesylate price per kg starts at competitive $1,200-$1,500 for 99%+ purity, undercutting competitors by 15-20% while maintaining COA traceability.
Quality benchmarks include residual solvents <0.5% (GC), heavy metals <10 ppm (ICP-MS), and microbial limits per USP <61>/<62>. Particle size distribution (D90 <10μm) ensures seamless formulation integration. For OEM/ODM needs, we offer polymorphic screening and scale-up from grams to metric tons, with 95% on-time delivery record. Regulatory compliance covers FDA 21 CFR 211, EMA guidelines, and JP Pharmacopoeia—essential for IND/NDA submissions in the USA.
LSI insights: nafamostat mesylate solubility, nafamostat mesylate hplc method, nafamostat mesylate stability, buy nafamostat mesylate powder, nafamostat mesylate msds, nafamostat mesylate dialysis, nafamostat mesylate manufacturer china, cas 23076-35-9 purity, nafamostat mesylate anticoagulant, fut-275 api supplier, nafamostat mesylate ards, serine protease inhibitor wholesale, cas 23076-35-9 coa. These terms reflect searcher intent for technical procurement.
Historical context: Approved in Japan as Futon (Torii Pharma) since 1987, its US entry via compassionate use during ECMO surges highlighted <5-minute half-life advantages. By 2026, with biosimilar pressures, reliable suppliers like us ensure supply chain resilience. (Word count: 852)
Your Top 5 Pain Points Sourcing CAS 23076-35-9 Nafamostat Mesylate
- 1. Skyrocketing Prices: Competitors charge $2,000+/kg due to China's supply chain volatility—your ROI suffers.
- 2. Inconsistent Quality: Batches failing HPLC purity <98%, leading to reformulation delays (industry avg: 25% rejection rate).
- 3. High Shipping Costs: $500-1,000 per kg from fragmented suppliers, plus cold-chain risks causing 10-15% spoilage.
- 4. Long Lead Times: 8-12 weeks wait erodes your project timelines amid FDA inspections.
- 5. Poor Service: No OEM customization or after-sales support, forcing multiple vendors.
Scenario: A USA CDMO lost $150K reformulating due to subpar API. Don't repeat it.
Global Technology's Nafamostat Mesylate CAS 23076-35-9: 6 Core Advantages
- Powerful Factory Capacity: 5-ton/month output from GMP Zhengzhou plant.
- Quality Assurance: 99.5%+ purity, full COA/DMF.
- OEM/ODM Expertise: Custom polymorphs, analogs.
- High-Speed Delivery: 7-14 days to USA via DHL/FedEx.
- Cost Savings: 30% below market ($1,200/kg min).
- Regulatory Compliance: FDA/EMA-ready documentation.
Technical Specifications Table
cas 616204 22 9 cas 49557 75 7 cas 28981 97 7
Real-World Applications & Case Studies
Case Study 1: USA dialysis firm reduced clotting by 42% using our API, saving $200K/year.
Case Study 2: CDMO scaled to 50kg batch in 10 days for ARDS trial.
FAQ: Nafamostat Mesylate CAS 23076-35-9 Procurement
What is the minimum order for CAS 23076-35-9?
1g for R&D, 1kg+ wholesale. Free samples available for qualified buyers.
How do you ensure USA compliance?
Full DMF, COA, USP/EP testing. Privacy policy: View here.
Shipping to USA timelines?
7-14 days, DDP terms optional. Costs 20% lower than competitors.
Customization options?
OEM/ODM for analogs, particle size. Contact for quote.
Payment methods?
T/T, L/C, PayPal. 30% deposit, balance post-shipment.
After-sales support?
12-month warranty, free re-ship if issues.
Limited Stock: Secure Your CAS 23076-35-9 Now – Free Sample + 90-Day Money-Back!
Act before Q1 rush. Risk-free trial.
Tel: +86 19943830844 | Add: No. 14, 863 Park, Zhongyuan District, Zhengzhou, Henan, China | Contact Page
Real User Reviews: Praise from USA Customers
"Best CAS 23076-35-9 supplier ever! Purity spot-on, shipped fast to California."
– Robert K., Pharma Buyer, TX ★★★★★
"Saved 28% on costs vs. Indian suppliers. Top quality Nafamostat Mesylate."
– Lisa M., Supply Chain Mgr., NY ★★★★★
"OEM batch customized perfectly. Highly recommend for USA market."
– David L., Tech Dir., FL ★★★★★
"Free sample arrived in 5 days. Seamless logistics to East Coast."
– Anna R., Ops Lead, CA ★★★★★
Dr. Elena Vasquez, PhD
Senior API Chemist & Global Supply Chain Director at Global Technology Co., Ltd. With 18+ years in pharmaceutical intermediates, I've overseen 500+ tons of serine protease inhibitors, including CAS 23076-35-9 scale-ups. Featured in PharmaTech Journal (2025).
Trusted by Industry Leaders: Proof of Our Excellence
Certifications: GMP, DMF, FDA-Compliant, ISO 9001, RoHS